Clinical trial
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
NCT00413205 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00413205 |
|---|---|
| Title | TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) |
| Official title | A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Emphysema |
| Intervention type | Drug |
| Interventions | Placebo, RAR Gamma |
| Enrollment | 491 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Dec 19, 2006 |
| Last update posted | Nov 2, 2016 |
| Countries | Bulgaria, Czechia, Hungary, Iceland, Israel, Italy, Latvia, Poland, South Africa, Ukraine, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: